English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background Mutations in the GFPT1 and DPAGT1 genes, which encode enzymes associated with roles in protein N-linked glycosylation, have been recently identified in a rare subgroup of patients with congenital myasthenic syndromes (CMSs). These mutations are inherited in an autosomal recessive pattern, and the mechanism of impaired neuromuscular transmission may be acetylcholine receptor (AChR) deficiency due to impaired (AChR) subunit glycosylation. Aberrant protein glycosylation is also implicated in the development of severe cardiomyopathies in the congenital disorders of glycosylation, although the mechanisms responsible for cardiac involvement are unknown. We investigated whether patients with CMS and GFPT1 or DPAGT1 mutations also had evidence of a cardiac phenotype. Methods We performed comprehensive cardiovascular magnetic resonance (CMR) imaging at 1.5T (Avanto, Siemens), 31P spectroscopy at 3T (Tim Trio, Siemens) and echocardiography to evaluate cardiac structure and function in patients with GFPT1 (n = 2) and DPAGT1 (n = 2) mutations. The mean age of the participants was 45 (range 25-57) and two were male. Results Electrocardiography was abnormal in all, with abnormal repolarisation and deep S waves (n = 3) or marked left ventricular hypertrophy by voltage criteria (n = 1). Despite normal biventricular volumes and systolic function, GFPT1/DPAGT1 patients demonstrated late gadolinium enhancement suggestive of myocardial fibrosis (n = 4, mean proportion of enhanced myocardium > 5 SD above individual reference regions 3.2% +/-1.6, Figure 1), impaired energetics (n = 2) and diastolic dysfunction (n = 3). No patient had symptoms attributable to cardiovascular disease on structured interview. Conclusions Patients with GFPT1 or DPAGT1 mutations demonstrate a cardiac phenotype including abnormal electrocardiography, myocardial fibrosis, diastolic dysfunction and impaired energetics, despite normal systolic function. These findings may reflect incipient cardiomyopathy due to aberrant cardiac glycoprotein function. The reason for

Characterisation of a novel cardiac phenotype in patients with GFPT1 or DPAGT1 mutations